BAY-876|cas:1799753-84-6|西域试剂

BAY-876,98.04%

产品编号：Bellancom-100017| CAS NO：1799753-84-6| 分子式：C₂₄H₁₆F₄N₆O₂| 分子量：496.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100017	￥990.00	杭州北京（现货）
Bellancom-100017	￥1400.00	杭州北京（现货）
Bellancom-100017	￥2200.00	杭州北京（现货）
Bellancom-100017	￥7100.00	杭州北京（现货）
Bellancom-100017	￥11000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BAY-876

产品介绍

BAY-876 是一种具有口服活性的，选择性的葡萄糖转运蛋白 1 (GLUT1) 抑制剂，IC₅₀ 为 2 nM。BAY-876 对 GLUT1 的选择性是 GLUT2，GLUT3 和 GLUT4 的 130 倍以上。BAY-876 还是一种糖酵解代谢和卵巢癌生长的有效阻滞剂。

生物活性

BAY-876 is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC₅₀ of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth.

体外研究

BAY-876 (25-75 nM; 24 and 72 hours) has the growth-inhibitory effect and leads to a dose-dependent decrease in numbers of SKOV-3 and OVCAR-3 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	SKOV-3 and OVCAR-3 cells
Concentration:	25, 50, 75 nM
Incubation Time:	24 and 72 hours
Result:	Led to a dose-dependent decrease in numbers of SKOV-3 and OVCAR-3 cells.

体内研究
(In Vivo)

BAY-876 (oral administration; 1.5-4.5 mg/kg/day for 28 days) causes a clear dose-dependent inhibition of tumorigenicity in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NOD-scid IL2rg^null (NSG) mice carrying SKOV-3 subcutaneous (s.c.) xenografts
Dosage:	1.5, 3, 4.5 mg/kg
Administration:	Oral administration; daily; for 28 days
Result:	Caused a clear dose-dependent inhibition of tumorigenicity.

体内研究

BAY-876 (oral administration; 1.5-4.5 mg/kg/day for 28 days) causes a clear dose-dependent inhibition of tumorigenicity in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NOD-scid IL2rg^null (NSG) mice carrying SKOV-3 subcutaneous (s.c.) xenografts
Dosage:	1.5, 3, 4.5 mg/kg
Administration:	Oral administration; daily; for 28 days
Result:	Caused a clear dose-dependent inhibition of tumorigenicity.

体内研究

BAY-876 (oral administration; 1.5-4.5 mg/kg/day for 28 days) causes a clear dose-dependent inhibition of tumorigenicity in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NOD-scid IL2rg^null (NSG) mice carrying SKOV-3 subcutaneous (s.c.) xenografts
Dosage:	1.5, 3, 4.5 mg/kg
Administration:	Oral administration; daily; for 28 days
Result:	Caused a clear dose-dependent inhibition of tumorigenicity.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (201.44 mM)

Methanol : 1 mg/mL (2.01 mM; ultrasonic and warming and heat to 60°C)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0144 mL	10.0721 mL	20.1442 mL
5 mM	0.4029 mL	2.0144 mL	4.0288 mL
10 mM	0.2014 mL	1.0072 mL	2.0144 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 50% PEG300 50% saline
Solubility: 5 mg/mL (10.07 mM); Suspended solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.04 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.04 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。